Case series of dementia with Lewy bodies: consensus criteria in practice

2019 ◽  
Vol 28 (1) ◽  
pp. 80-83
Author(s):  
Richard Goodwin
Keyword(s):  
Mental Health ◽  
Neurodegenerative Disorders ◽  
Early Identification ◽  
Dementia With Lewy Bodies ◽  
Case Series ◽  
Lewy Bodies ◽  
Assessment Tools ◽  
Newly Diagnosed ◽  
Psychiatric Illnesses

Objectives: This case series considers three patients newly diagnosed with dementia with Lewy bodies (DLB) whilst under the care of mental health services. The cases demonstrate that the difficulties in diagnosing DLB as early symptoms may resemble other neurodegenerative disorders or psychiatric illnesses. Conclusion: The role of consensus criteria in diagnosis is explored. The use of screening and assessment tools in early identification of DLB is also considered.

Thalamocortical dysfunction and complex visual hallucinations in brain disease – Are the primary disturbances in the cerebral cortex?

2004 ◽  
Vol 27 (6) ◽  
pp. 789-790 ◽  
Author(s):  
Daniel Collerton ◽  
Elaine Perry
Keyword(s):  
Cerebral Cortex ◽  
Progressive Supranuclear Palsy ◽  
Neurodegenerative Disorders ◽  
Dementia With Lewy Bodies ◽  
Sensory Input ◽  
Lewy Bodies ◽  
Brain Disease ◽  
Visual Hallucinations ◽  
Eye Closure

Applying Behrendt & Young's (B&Y's) model of thalamocortical synchrony to complex visual hallucinations in neurodegenerative disorders, such as dementia with Lewy bodies and progressive supranuclear palsy, leads us to propose that the primary pathology may be cortical rather than thalamic. Additionally, the extinction of active hallucinations by eye closure challenges their conception of the role of reduced sensory input.

scholarly journals Examining the Toxicity of α-Synuclein in Neurodegenerative Disorders

Life ◽  
2021 ◽  
Vol 11 (11) ◽  
pp. 1126
Author(s):  
Frank Y. Shan ◽  
Kar-Ming Fung ◽  
Tarek Zieneldien ◽  
Janice Kim ◽  
Chuanhai Cao ◽  
...  
Keyword(s):  
Multiple System Atrophy ◽  
Disease Progression ◽  
Amyloid Beta ◽  
Targeted Therapies ◽  
Neurodegenerative Disorders ◽  
Dementia With Lewy Bodies ◽  
Lewy Bodies ◽  
Post Translational Modifications ◽  
Mechanisms Of Toxicity

α-synuclein is considered the main pathological protein in a variety of neurodegenerative disorders, such as Parkinson’s disease, multiple system atrophy, and dementia with Lewy bodies. As of now, numerous studies have been aimed at examining the post-translational modifications of α-synuclein to determine their effects on α-synuclein aggregation, propagation, and oligomerization, as well as the potential cellular pathway dysfunctions caused by α-synuclein, to determine the role of the protein in disease progression. Furthermore, α-synuclein also appears to contribute to the fibrilization of tau and amyloid beta, which are crucial proteins in Alzheimer’s disease, advocating for α-synuclein’s preeminent role in neurodegeneration. Due to this, investigating the mechanisms of toxicity of α-synuclein in neurodegeneration may lead to a more proficient understanding of the timeline progression in neurodegenerative synucleinopathies and could thereby lead to the development of potent targeted therapies.

Dementia with Lewy bodies

2018 ◽  
pp. 11-21
Author(s):  
O. S. Levin ◽  
E. E. Vasenina ◽  
A. Sh. Chimagomedova ◽  
N. G. Dudchenko
Keyword(s):  
Parkinson’S Disease ◽  
Dementia With Lewy Bodies ◽  
Cholinesterase Inhibitors ◽  
Lewy Bodies ◽  
Diagnosis And Treatment ◽  
Modern Concept ◽  
Historical Aspect ◽  
Neurodegenerative Process ◽  
Icd 10

Te lecture presents modern concept of the symptoms, diagnosis and treatment of dementia with Lewy bodies (DLB), which accounts for about 10% of cases of dementia. Te nosological status of DLB and the problem of ratio of DLB and Parkinson’s disease which, apparently, represent two phenotypic variants of one neurodegenerative process («diseases with Lewy bodies») are considered in historical aspect. Approaches to the diagnosis and coding of DLB in accordance with ICD-10 are proposed. Te role of cholinesterase inhibitors, antipsychotics, levodopa, rasagiline and other drugs in the treatment of patients with DLB is аnalyzed.

scholarly journals Lost in a Dream

2019 ◽  
pp. 381-396
Author(s):  
Carlos L. Rodriguez ◽  
Babak Tousi
Keyword(s):  
Motor Neurons ◽  
Neurodegenerative Disorders ◽  
Dementia With Lewy Bodies ◽  
Neurodegenerative Disorder ◽  
Lewy Bodies ◽  
Behavior Disorder ◽  
Sleep Behavior ◽  
The Relationship ◽  
Over Time

Rapid-eye-movement sleep behavior disorder (RBD) is a parasomnia that is closely associated with neurodegenerative disorders. RBD is usually caused by neurodegeneration within the brainstem that disables the system responsible for immobilizing skeletal muscles during REM sleep and thus permits motor neurons to activate these muscles during dreaming. The underlying source of the brainstem neurodegeneration spreads over time to other central nervous system regions until it has sufficiently evolved to permit clinical recognition of the underlying neurodegenerative disorder. Longitudinal follow-up of patients with RBD has demonstrated that most patients subsequently develop some neurodegenerative disorder years later, particularly the synucleinopathies. We review the relationship between RBD and dementia with Lewy bodies, which is one of the synucleinopathies. The management of RBD is reviewed with discussion of the relevant considerations in patients with dementia with Lewy bodies.

scholarly journals Quality of Life in Patients with Dementia with Lewy Bodies

2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Chuo-Yu Lee ◽  
Shih-Jung Cheng ◽  
Hui-Chi Lin ◽  
Yu-Lu Liao ◽  
Pei-Hao Chen
Keyword(s):  
Quality Of Life ◽  
Daily Living ◽  
Dementia With Lewy Bodies ◽  
Lewy Bodies ◽  
Controlled Study ◽  
Randomized Controlled ◽  
Specific Instrument ◽  
Pubmed Database

Dementia with Lewy bodies (DLB) is a complex, multisymptom disorder. When making decisions regarding the treatment of DLB, the patient’s quality of life (QoL) should always be the main consideration. To our knowledge, this is the first review article focusing on the QoL in DLB patients. We searched the PubMed database using the keywords “quality of life” and “dementia with Lewy bodies.” Previously, no specific instrument had been developed for assessing the QoL in DLB patients. Patients with DLB have a decreased QoL compared to patients with Alzheimer’s disease, which is reportedly caused by several factors including level of independence in instrumental activities of daily living, whether the patient is living with the caregiver, apathy, delusion, and dysautonomia. The direct effect of visual hallucination, sleep, and movement disorders on the QoL in DLB patients has not been previously studied. The role of cognitive function on the QoL is still controversial. In a randomized controlled study, memantine may improve the QoL in PDD or DLB patients. We concluded that it is important to develop a specific instrument to assess the QoL in DLB patients. Furthermore, there is an urgent need for large clinical trials to identify factors associated with the QoL and how they can be managed.

Sign in / Sign up

Export Citation Format

Share Document